AR064735A1 - Agonistas de gpcr y composicion farmaceutica en base al compuesto - Google Patents
Agonistas de gpcr y composicion farmaceutica en base al compuestoInfo
- Publication number
- AR064735A1 AR064735A1 ARP080100017A ARP080100017A AR064735A1 AR 064735 A1 AR064735 A1 AR 064735A1 AR P080100017 A ARP080100017 A AR P080100017A AR P080100017 A ARP080100017 A AR P080100017A AR 064735 A1 AR064735 A1 AR 064735A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutical composition
- composition based
- gpcr agonists
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Estos compuestos son agonistas del GPCR y son de utilidad para el tratamiento de la obesidad y la diabetes. Reivindicacion 1: Un compuesto de la formula (1) o una sal aceptable para uso farmacéutico del mismo: en el cual uno de X e Y es O y el otro es N; uno de E y Q es N y el otro es CH; R1 es SO2R5 o -CONHR5; R2 es hidrogeno o metilo, R3 es hidrogeno o metilo, R4 es alquilo C2-5; R5 es alquilo C1-3, y R6 es H, alquilo C1-3 o alquilo C2-3 sustituido con hidroxi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0700125A GB0700125D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
GB0708746A GB0708746D0 (en) | 2007-05-08 | 2007-05-08 | GPCR agonists |
GB0719763A GB0719763D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064735A1 true AR064735A1 (es) | 2009-04-22 |
Family
ID=39199058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100017A AR064735A1 (es) | 2007-01-04 | 2008-01-03 | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100105732A1 (es) |
EP (2) | EP2377864A1 (es) |
JP (1) | JP2010514831A (es) |
AR (1) | AR064735A1 (es) |
AT (1) | ATE517103T1 (es) |
BR (1) | BRPI0806500A2 (es) |
CA (1) | CA2674455A1 (es) |
CL (1) | CL2008000018A1 (es) |
CY (1) | CY1112474T1 (es) |
DK (1) | DK2114935T3 (es) |
EA (1) | EA015130B1 (es) |
HK (1) | HK1135705A1 (es) |
HR (1) | HRP20110750T1 (es) |
PE (1) | PE20081659A1 (es) |
PL (1) | PL2114935T3 (es) |
PT (1) | PT2114935E (es) |
RS (1) | RS51943B (es) |
SA (1) | SA08280757B1 (es) |
SI (1) | SI2114935T1 (es) |
TW (1) | TW200835482A (es) |
WO (1) | WO2008081207A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0516407A (pt) * | 2004-12-24 | 2008-09-02 | Prosidion Ltd | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes |
US20100063081A1 (en) * | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
PE20081849A1 (es) * | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
US20100286112A1 (en) | 2007-09-10 | 2010-11-11 | Oscar Barba | Compounds for the treatment of metabolic disorders |
CN101868452B (zh) | 2007-10-10 | 2014-08-06 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812641D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
ES2403120T3 (es) * | 2008-12-24 | 2013-05-14 | Cadila Healthcare Limited | Nuevos derivados de oxima |
GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
TW201111361A (en) | 2009-06-24 | 2011-04-01 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN104610390A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途 |
CN104610393A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
US6100042A (en) * | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
FR2705346B1 (fr) * | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
WO1997015567A1 (de) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
EP0934941A1 (en) | 1996-08-09 | 1999-08-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
EP1112359A2 (en) | 1998-09-01 | 2001-07-04 | BASF Aktiengesellschaft | Enhanced functional expression of g protein-coupled receptors |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
KR100635892B1 (ko) * | 2000-11-21 | 2006-10-18 | 미쓰비시 가가꾸 가부시키가이샤 | 2-(4-피리딜)에탄티올의 제조 방법 |
FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
AU2002333853B2 (en) | 2001-09-21 | 2006-07-13 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
UA78523C2 (en) | 2001-09-21 | 2007-04-10 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
US20040248956A1 (en) | 2002-01-29 | 2004-12-09 | Hagmann William K | Substituted imidazoles as cannabinoid receptor modulators |
US20050171161A1 (en) | 2002-03-06 | 2005-08-04 | Fong Tung M. | Method of treatment or prevention of obesity |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
CA2479618A1 (en) | 2002-03-26 | 2003-10-09 | William K. Hagmann | Spirocyclic amides as cannabinoid receptor modulators |
ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
AU2003226149A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
WO2003086288A2 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Bicyclic amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
AU2003250117B2 (en) | 2002-07-29 | 2007-05-10 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
AU2003257145B2 (en) | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
US20050101542A1 (en) | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
AR041268A1 (es) | 2002-09-19 | 2005-05-11 | Solvay Pharm Bv | Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen |
US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
CA2502511A1 (en) | 2002-10-18 | 2004-05-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
EP1575901B1 (en) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
MXPA05007114A (es) | 2003-01-02 | 2005-08-26 | Hoffmann La Roche | Nuevos agonistas inversos del receptor cb1. |
JP4271660B2 (ja) | 2003-01-02 | 2009-06-03 | エフ.ホフマン−ラ ロシュ アーゲー | ピロリル−チアゾール及びcb1受容体逆作動物質としてのその使用 |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
MXPA05007516A (es) | 2003-02-13 | 2006-01-27 | Sanofi Aventis Deutschland | Derivados de hexahidropirazino[1,2-a]pirimidina -4, 7-diona sustituidos, metodo para producirlos y su uso como medicamentos. |
BRPI0407387A (pt) | 2003-02-13 | 2006-02-07 | Aventis Pharma Gmbh | Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento |
US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
US20060172019A1 (en) | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
WO2005061489A1 (en) | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
BRPI0516407A (pt) | 2004-12-24 | 2008-09-02 | Prosidion Ltd | agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes |
US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
US20100063081A1 (en) * | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
WO2007003961A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
US20090203676A1 (en) | 2005-06-30 | 2009-08-13 | Oscar Barba | G-protein Coupled Receptor Agonists |
WO2007116229A1 (en) * | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
EP2094683B1 (en) * | 2006-12-06 | 2011-10-12 | GlaxoSmithKline LLC | Bicyclic compounds and use as antidiabetics |
PE20081849A1 (es) * | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
-
2008
- 2008-01-03 PE PE2008000084A patent/PE20081659A1/es not_active Application Discontinuation
- 2008-01-03 AR ARP080100017A patent/AR064735A1/es unknown
- 2008-01-03 CL CL200800018A patent/CL2008000018A1/es unknown
- 2008-01-04 RS RS20110448A patent/RS51943B/en unknown
- 2008-01-04 WO PCT/GB2008/050013 patent/WO2008081207A1/en active Application Filing
- 2008-01-04 PL PL08702096T patent/PL2114935T3/pl unknown
- 2008-01-04 SI SI200830401T patent/SI2114935T1/sl unknown
- 2008-01-04 AT AT08702096T patent/ATE517103T1/de active
- 2008-01-04 EP EP11169308A patent/EP2377864A1/en not_active Withdrawn
- 2008-01-04 DK DK08702096.2T patent/DK2114935T3/da active
- 2008-01-04 CA CA002674455A patent/CA2674455A1/en not_active Abandoned
- 2008-01-04 PT PT08702096T patent/PT2114935E/pt unknown
- 2008-01-04 JP JP2009544450A patent/JP2010514831A/ja active Pending
- 2008-01-04 EA EA200900880A patent/EA015130B1/ru not_active IP Right Cessation
- 2008-01-04 TW TW097100416A patent/TW200835482A/zh unknown
- 2008-01-04 BR BRPI0806500-4A2A patent/BRPI0806500A2/pt not_active IP Right Cessation
- 2008-01-04 EP EP08702096A patent/EP2114935B1/en active Active
- 2008-01-04 US US12/522,023 patent/US20100105732A1/en not_active Abandoned
- 2008-01-05 SA SA8280757A patent/SA08280757B1/ar unknown
-
2010
- 2010-04-16 HK HK10103733.4A patent/HK1135705A1/xx not_active IP Right Cessation
-
2011
- 2011-10-14 HR HR20110750T patent/HRP20110750T1/hr unknown
- 2011-10-17 CY CY20111100985T patent/CY1112474T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PE20081659A1 (es) | 2008-10-24 |
PL2114935T3 (pl) | 2012-03-30 |
PT2114935E (pt) | 2011-10-17 |
EP2377864A1 (en) | 2011-10-19 |
HK1135705A1 (en) | 2010-06-11 |
JP2010514831A (ja) | 2010-05-06 |
BRPI0806500A2 (pt) | 2014-04-22 |
EA015130B1 (ru) | 2011-06-30 |
EP2114935B1 (en) | 2011-07-20 |
WO2008081207A1 (en) | 2008-07-10 |
CA2674455A1 (en) | 2008-07-10 |
HRP20110750T1 (hr) | 2011-11-30 |
CY1112474T1 (el) | 2015-12-09 |
TW200835482A (en) | 2008-09-01 |
ATE517103T1 (de) | 2011-08-15 |
SI2114935T1 (sl) | 2011-11-30 |
DK2114935T3 (da) | 2011-10-31 |
CL2008000018A1 (es) | 2008-08-01 |
RS51943B (en) | 2012-02-29 |
EP2114935A1 (en) | 2009-11-11 |
US20100105732A1 (en) | 2010-04-29 |
EA200900880A1 (ru) | 2010-02-26 |
SA08280757B1 (ar) | 2011-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064735A1 (es) | Agonistas de gpcr y composicion farmaceutica en base al compuesto | |
AR064736A1 (es) | Agonistas de gpcr | |
CY1112483T1 (el) | Αγωνιστες gpcr πιπεριδινης | |
ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
PE20120218A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
MX2009003972A (es) | Compuesto de indol. | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
ATE479677T1 (de) | Pyrimidinderivate als gpcr-agonisten | |
TN2012000002A1 (en) | Gpr119 agonists | |
NO20083480L (no) | Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister | |
SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
PE20110329A1 (es) | Agonistas del receptor acoplado a la proteina g piperidinilo | |
AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
PE20070498A1 (es) | Compuestos derivados de indoles de acilo como antagonistas del receptor de glucagon | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
AR064521A1 (es) | Activador de glucoquinasa | |
PE20120648A1 (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1 | |
GB0812642D0 (en) | Compounds | |
CO6150175A2 (es) | Compuesto triciclico y uso farmaceutico del mismo | |
PE20091890A1 (es) | COMPUESTOS DE 3-FENILPIRAZOLO [5,1-b] TIAZOL | |
AR065724A1 (es) | Macrolidos | |
PE20090771A1 (es) | Derivados de cinolina | |
AR065864A1 (es) | Compuesto de oxi-ciclohexil-piperidinil-dihidro-benzimidazol-2-ona composicion farmacetica que lo comprende su uso para la preparacion de un medicamento y compuestos intermediarios para su preparacion | |
TH109166A (th) | อะโกนิสต์ของ gpcr | |
TH105091A (th) | อะโกนิสต์ของ gpcr |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |